×
About 805 results

ALLMedicine™ Blastic Plasmacytoid Dendritic Cell Center

Research & Reviews  242 results

TET2 truncating mutations predict a worse outcome in blastic plasmacytoid dendritic cel...
https://doi.org/10.1182/bloodadvances.2022007879
Blood Advances; Beird HC, Yin CC et. al.

Jan 24th, 2023 - TET2 truncating mutations predict a worse outcome in blastic plasmacytoid dendritic cell neoplasm.|2023|Beird HC,Yin CC,Khoury JD,Pierce SR,Abbas HA,|

Plasmacytoid dendritic cells in the setting of myeloid neoplasms: Diagnostic guide to c...
https://doi.org/10.1111/bjh.18632
British Journal of Haematology; El Hussein S, Wang W

Jan 7th, 2023 - In this article, we describe three broad pathologic presentations of plasmacytoid dendritic cells (pDCs) that may be encountered in clinical practice, in which an association between pDCs and myeloid neoplasms is identified: (1) myeloid neoplasms ...

Genetically Modified T-cell Immunotherapy in Treating Patients With Relapsed/Refractory Acute Myeloid Leukemia and Persistent/Recurrent Blastic Plasmacytoid Dendritic Cell Neoplasm
https://clinicaltrials.gov/ct2/show/NCT02159495

Jan 5th, 2023 - PRIMARY OBJECTIVES: I. To examine the anti-tumor activity and safety of administering ex vivo expanded T cells that are genetically modified using a self-inactivating (SIN) lentiviral vector to express a co-stimulatory CD123-specific chimeric anti...

Retrospective analysis of hematopoietic cell transplantation for blastic plasmacytoid d...
https://doi.org/10.1038/s41375-022-01782-z
Leukemia Bruch PM, Dietrich S et. al.

Dec 23rd, 2022 - Blastic plasmacytoid dendritic cell neoplasia (BPDCN) is a rare myeloid malignancy with a generally poor prognosis. Although preliminary evidence suggests that hematopoietic cell transplantation (HCT) could improve outcome in patients with BPDCN, ...

Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN) International Registry
https://clinicaltrials.gov/ct2/show/NCT05430971

Dec 23rd, 2022 - Blastic plasmacytoid dendritic cell neoplasm (BPDCN) is a rare hematologic malignancy. In 2008, it was recognized by the WHO as a distinct entity and separately listed in the group of acute myeloid leukemias and related precursor neoplasms. The fi...

see more →

Drugs  2 results see all →

Clinicaltrials.gov  13 results

Genetically Modified T-cell Immunotherapy in Treating Patients With Relapsed/Refractory Acute Myeloid Leukemia and Persistent/Recurrent Blastic Plasmacytoid Dendritic Cell Neoplasm
https://clinicaltrials.gov/ct2/show/NCT02159495

Jan 5th, 2023 - PRIMARY OBJECTIVES: I. To examine the anti-tumor activity and safety of administering ex vivo expanded T cells that are genetically modified using a self-inactivating (SIN) lentiviral vector to express a co-stimulatory CD123-specific chimeric anti...

Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN) International Registry
https://clinicaltrials.gov/ct2/show/NCT05430971

Dec 23rd, 2022 - Blastic plasmacytoid dendritic cell neoplasm (BPDCN) is a rare hematologic malignancy. In 2008, it was recognized by the WHO as a distinct entity and separately listed in the group of acute myeloid leukemias and related precursor neoplasms. The fi...

The Myeloid Neoplasms Biology and Outcome Project
https://clinicaltrials.gov/ct2/show/NCT05074316

Nov 22nd, 2022 - During recent years, considerable progress has been made in deciphering the molecular genetic and epigenetic basis of myeloid neoplasms and in defining new diagnostic and prognostic as well as predictive markers. Myeloid neoplasms are categorized ...

Tagraxofusp in Pediatric Patients With Relapsed or Refractory CD123 Expressing Hematologic Malignancies
https://clinicaltrials.gov/ct2/show/NCT05476770

Nov 15th, 2022 - Tagraxofusp is a protein-drug conjugate consisting of a diphtheria toxin redirected to target CD123 has been approved for treatment in pediatric and adult patients with blastic plasmacytoid dendritic cell neoplasm (BPDCN). This trial aims to exami...

Venetoclax, SL-401, and Chemotherapy for the Treatment of Blastic Plasmacytoid Dendritic Cell Neoplasm
https://clinicaltrials.gov/ct2/show/NCT04216524

Sep 23rd, 2022 - PRIMARY OBJECTIVE: I. To evaluate progression-free survival (PFS) at 12 months of venetoclax (VEN) in combination with chemotherapy and SL-401 (tagraxofusp [TAG]) in patients with newly diagnosed blastic plasmacytoid dendritic cell neoplasm (BPDCN...

see more →

News  65 results

Dr. Wang on the Current Treatment Options for BPDCN
https://www.onclive.com/view/dr-wang-on-the-current-treatment-options-for-bpdcn

Nov 21st, 2022 - Eunice Wang, MD, chief the Leukemia Service, the Department of Medicine, Roswell Park Comprehensive Cancer Center, discusses the current treatment options for blastic plasmacytoid dendritic cell neoplasm (BPDCN). Up-front treatment for patients w...

'Nothing Is Guaranteed'; Cancer and Suicide Risk; 'Lawyers Are Circling'
https://www.medpagetoday.com/hematologyoncology/othercancers/100523

Sep 2nd, 2022 - "Nothing is guaranteed." NFL head coach Ron Rivera of the Washington Commanders talks about how cancer changes a person's life. (ESPN) The FDA announced that Intera Oncology has issued a recall for the Intera 3000 infusion pump following reports o...

Frontline Pivekimab Sunirine Demonstrates Significant Activity in Blastic Plasmacytoid Dendritic Cell Neoplasm
https://www.onclive.com/view/frontline-pivekimab-sunirine-demonstrates-significant-activity-in-blastic-plasmacytoid-dendritic-cell-neoplasm

Aug 31st, 2022 - First-line treatment with pivekimab sunirine (IMGN632) generated responses with favorable tolerability in patients with blastic plasmacytoid dendritic cell neoplasm (BPDCN), according to data from the phase 2 CADENZA trial (NCT03386513).1 Among...

Isolated Nodule and Generalized Lymphadenopathy
https://www.mdedge.com/dermatology/article/252525/dermatopathology/isolated-nodule-and-generalized-lymphadenopathy
Yahya Daneshbod, MD, Michael Greas, MD et. al.

Mar 8th, 2022 - The Diagnosis: Blastic Plasmacytoid Dendritic Cell Neoplasm A diagnosis of blastic plasmacytoid dendritic cell neoplasm (BPDCN) was rendered. Subsequent needle core biopsy of a left axillary lymph node as well as bone marrow aspiration and biopsy.

Tagraxofusp and Hyper-CVAD Represent Treatment Options for Patients with BPDCN
https://www.onclive.com/view/tagraxofusp-and-hyper-cvad-represent-treatment-options-for-patients-with-bpdcn

Feb 3rd, 2022 - Despite the rarity of patients diagnosed with blastic plasmacytoid dendritic cell neoplasm (BPDCN), 2 studies examining treatment options for the disease produced encouraging results and safety data, according to Naveen Pemmaraju, MD. Pemmaraju p...

see more →